Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
OBJECTIVE
To determine if intravenous high-dose "pulse" glucocorticoid therapy induced remission or reduced subsequent requirements for orally administered glucocorticoids in pemphigus vulgaris.


METHODS
Retrospective, case-controlled study.


METHODS
Academic referral center.


METHODS
Fifteen patients, all of whom had pemphigus vulgaris, were included in the analysis. The group comprised all patients with pemphigus vulgaris seen during 11.5 years who did not initially respond to low doses (< 40 mg/d) of prednisone and who were followed up for at least 500 days after beginning treatment.


METHODS
One group received very high-dose intravenous pulse(s) of methylprednisolone sodium succinate (Solu-Medrol) (n = 9). The other group did not receive intravenous pulse therapy (n = 6).


METHODS
Glucocorticoid dose and status of disease.


RESULTS
Patients treated with pulse therapy and control patients treated with conventional oral prednisone had similar initial disease severity. Six of the 9 patients who received pulse therapy showed improvement of their pemphigus vulgaris, and 4 of the 9 had discontinued all glucocorticoids and were in remission at mean (+/- SEM) 269 +/- 27 days. They have continued in remission without receiving prednisone for a mean of 714 +/- 142 days. Therapeutic benefit was seen in patients who received pulse therapy early or late after beginning glucocorticoid therapy. In contrast, none of the 6 control patients has achieved long-term remissions without therapy. All of the controls have had long courses of glucocorticoid therapy, with a mean of 1467 +/- 112 days of prednisone treatment. Overall, the mean (+/- SEM) prednisone dose between days 350 and 500 from onset of glucocorticoid therapy was 9.2 +/- 4.2 mg/d for those who received pulse therapy vs 21.0 +/- 3.3 mg/d (P < .05) for those who did not (unpaired 2-tailed t test).


CONCLUSIONS
High-dose pulse administration of glucocorticoids is a potentially effective therapy to be considered in the treatment of patients with severe pemphigus vulgaris. Similar patients treated with conventional orally administered doses of prednisone had protracted courses requiring years of glucocorticoid therapy with no long-term remissions.
Werth
V P
VP
Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010392:Pemphigus / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011241:Prednisone; D008775:Methylprednisolone